London, United Kingdom, September 2025 — LifeArc has announced the permanent appointment of Adrien Lemoine as Chief Business Officer, following his interim tenure in the role since May 2025. With more than two decades of experience in the pharmaceutical and biotech industry, Adrien brings deep expertise in entrepreneurship, business development, R&D strategy, program management, and financing.
In his new capacity, Adrien will continue to lead business development and commercial strategy, ensuring strong alignment between LifeArc’s pioneering scientific innovation and its business objectives. His appointment reinforces LifeArc’s mission to transform promising life science ideas into medical breakthroughs that improve lives.
“I have seen first-hand how challenging it can be to fund and develop therapies for rare diseases, and LifeArc is truly uniquely placed to make a decisive impact in this ecosystem. I look forward to expanding LifeArc’s partnerships and to helping secure the resources needed to fulfil our vision and improve the lives of people living with rare diseases.” — Adrien Lemoine, Chief Business Officer, LifeArc
Adrien most recently co-founded and served as Chief Executive Officer of Bloomsbury Genetic Therapies, where he led efforts to develop curative gene therapy treatments for patients with rare neurological and metabolic diseases.
Previously, he held multiple senior leadership roles at Orchard Therapeutics, including Chief Business Officer and Senior Vice President, Business Development & Portfolio Strategy, where he was instrumental in driving alliance management and growth initiatives.
Adrien also served as Executive Director of Corporate Development at AstraZeneca, following nearly a decade at GlaxoSmithKline, where he advanced strategies in rare diseases and global product development. Earlier in his career, he worked with Corvidia Therapeutics, Kurma Partners, and Alcimed, gaining broad exposure to biotech strategy, portfolio management, and investment.
About LifeArc
LifeArc® is a medical research charity dedicated to making life science life changing by transforming early-stage scientific discoveries into medical breakthroughs. For over 25 years, LifeArc has specialized in advancing translational research, bridging the gap between lab-based science and real-world treatments.
Its work has already led to the development of diagnostics for antimicrobial resistance and four licensed medicines, including Keytruda® (cancer), Actemra® (rheumatoid arthritis), Tysabri® (multiple sclerosis), and Entyvio® (Crohn’s disease). LifeArc continues to play a pivotal role in driving innovation that addresses some of the world’s most pressing health challenges.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
